Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OBERTON: BCD-217 (Nurulimab + Prolgolimab) vs Prolgolimab in Advanced Melanoma
NCT03913923Phase 2Unknown
- Sponsor
- BIOCAD
- Start
- Jul 2019
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of nurulimab in melanoma (2 arms), sponsored by BIOCAD. Primary endpoint: Median Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
nurulimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03913923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913923.